A Single-site, Open-label, Non-comparator Clinical Trial to eLiminate HCV-infection in Treatment-naïve, EgyptiAn Patients With End-stage Renal Disease on Renal Dialysis, With Chronic Hepatitis C Genotype 4 Infection Using a 12-week Course of Once-daily Single Oral Tablet of Elbasvir (50mg)/Grazoprevir (100 mg)
Status: Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms CLEAR-C4
- 04 Mar 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Jun 2020.
- 04 Mar 2019 Planned initiation date changed from 1 Dec 2018 to 1 Dec 2019.
- 16 Jun 2018 Planned End Date changed from 1 Apr 2020 to 1 Jun 2020.